October 30, 2026
BURLINGTON, Ontario – October 30, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) (OTCQB: RDTCF) announces that it has agreed with certain of its creditors (the “Creditors”) to issue up to an aggregate of 5,000,000 common shares (the “Settlement Shares”) to...
October 21, 2026
BURLINGTON, Ontario – October 21, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin-film drug delivery technology, today announced that it has shipped a complete QuickStrip™ production line to Callan JMB Inc....
October 5, 2026
BURLINGTON, Ontario – October 5, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) (OTCQB: RDTCF), announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the “Notes”), the Company intends to issue...
August 20, 2026
Second granted nicotine oral-film patent strengthens RDT’s intellectual-property portfolio and its collaboration with a global nicotine industry leader, advancing the Company’s strategy to build a protected global nicotine delivery platform. BURLINGTON, Ontario — August 20, 2026 — Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE:...
July 28, 2026
BURLINGTON, Ontario — July 28, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“Rapid Dose” or “RDT”), a Canadian biotechnology company, and Ontario-based Bodhi Health Inc. (“Bodhi Health”) today announced an expansion of their coordinated distribution, sales and market-development efforts for Bodhi Health Sublingual...
July 10, 2026
BURLINGTON, Ontario – July 10, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the “Notes”), the Company issued common shares (“Common Shares”)...
July 7, 2026
Burlington, Ontario – July 7, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, is pleased to announce the execution of a Memorandum of Understanding (“MOU”) with a...
April 13, 2026
BURLINGTON, ON — April 13, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“RDT” or the “Company”), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario...
April 6, 2026
BURLINGTON, Ontario – April 1, 2026 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) (OTCQB: RDTCF) announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the “Notes”), the Company intends to issue...
March 26, 2026
BURLINGTON, Ontario – March 26, 2026 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“RDT” or the “Company”), a Canadian biotechnology leader specializing in innovative oral thin film drug delivery, is pleased to provide shareholders with a strategic update highlighting its continued execution, operational...